炎症と解消をプログラムした髄膜回路は,上皮および中皮三重陰性乳がんの治療抵抗を制御する
Liqun Yu1, Charlotte Rivas1, Fengshuo Liu1
1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, United States of America.
The Journal of clinical investigation
|February 17, 2026
まとめ
トリプルネガティブな乳がんは,治療の有効性を阻害する多様なマクロファージの集団を示しています. 共有アップストリームレギュレータをターゲットにすることで,炎症と解消経路を調節することによって,治療抵抗を克服する潜在的な戦略を提供します.
科学分野:
- 免疫学 免疫学とは
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
背景:
- トリプルネガティブ乳がん (TNBC) は,治療の選択肢が限られている攻撃的なサブタイプです.
- 腫瘍の微小環境,特にマクロファージのような免疫細胞は,治療反応と耐性において重要な役割を果たします.
- マクロファージの異質性を理解することは,TNBCにおける新しい治療戦略の開発に不可欠です.
研究 の 目的:
- ヒトのトリプルネガティブ乳がんにおけるマクロファージ集団の異質性を調査する.
- 治療抵抗性におけるプロ炎症性およびプロ解離性マクロファージの異なる役割を解明する.
- TNBCにおける治療抵抗性の克服のための潜在的な治療標的を特定する.
主な方法:
- ヒト乳がん腫瘍の単細胞RNA配列解析.
- マクロファージのフェノタイプとエピテリア型対メゼンキマ型腫瘍における局所化の分析.
- 観察されたパターンを再現し,治療的介入をテストするためにマウスモデルを使用しました.
- 免疫抑制における脂肪酸代謝 (ω-3とω-6) とC1qの役割を調査した.
主要な成果:
- 2つの異なるマクロファージのサブセットを特定した:プロ炎症性およびプロ解像性,どちらも治療抵抗性腫瘍に蓄積する.
- これらのサブセットの間の逆相関が実証され,相互排他的抵抗メカニズムが示唆されています.
- 異なる局所化パターンが観察された: 炎症性マクロファージは上皮状の腫瘍で,プロ解像性マクロファージはメゼンキマ状の腫瘍で.
- マクロファージによって分泌されるC1qがT細胞機能に敵対し, ω-6脂肪酸経路が上皮状腫瘍における免疫抑制に貢献することを示した.
- ELOVL5のノックダウンは,中性子とマクロファージの両方によって媒介される免疫抑制を緩和した.
結論:
- 異なるマクロファージ軸によって誘発される不規則な炎症と解消プログラムは,TNBCにおける治療による免疫監視を損なう.
- 溶解性マクロファージは,メゼンキマ型の腫瘍における ω-3の吸収と溶解素の産生を通じて抵抗性を促進する.
- 炎症性マクロファージと中性粒子は,表皮のような腫瘍における ω-6経路経由で抵抗を促進する.
- これらの異なる炎症軸の共有された上流調節体をターゲットにすることは,治療抵抗性を克服するための有望な戦略です.
関連する概念動画
Inflammatory Response
17.2K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
17.2K
The Tumor Microenvironment
7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Metastasis
6.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K


